Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
215,6 USD | -0,33% | -2,32% | -16,67% |
Vakgebied
- verkoop van geneesmiddelen (73,7%): voor de behandeling van multiple sclerose, chronische psoriasis bij volwassenen, reumatoïde artritis, kanker, enz;
- royalty's (17,2%) ;
- overige (9,1%): voornamelijk inkomsten uit samenwerkingsovereenkomsten.
Aantal werknemers: 7 570
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 10 173 | 100,0 % | 9 836 | 100,0 % | -3,32% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
55,2
%
| 5 532 | 54,4 % | 5 434 | 55,2 % | -1,77% |
Europe
21,8
%
| 2 413 | 23,7 % | 2 140 | 21,8 % | -11,34% |
Germany
8,8
%
| 926 | 9,1 % | 868 | 8,8 % | -6,28% |
Asia
8,8
%
| 720 | 7,1 % | 863 | 8,8 % | +19,97% |
Other
5,4
%
| 583 | 5,7 % | 531 | 5,4 % | -8,87% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 64 | 14-11-22 | |
Director of Finance/CFO | 60 | 15-08-20 | |
Nicole Murphy
COO | Chief Operating Officer | - | 01-01-15 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 57 | 02-10-23 |
Chuck Triano
IRC | Investor Relations Contact | - | 10-04-23 |
Michael Hencke
IRO | Public Communications Contact | - | 01-07-12 |
Michael Dambach
TRE | Treasurer | 57 | 01-01-07 |
Corporate Secretary | - | - | |
Robert Kilo
PRN | Corporate Officer/Principal | - | - |
Rachid Izzar
PRN | Corporate Officer/Principal | - | 01-01-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 01-01-10 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-19 |
Caroline Dorsa
CHM | Chairman | 64 | 03-01-10 |
Eric Rowinsky
BRD | Director/Board Member | 67 | 20-03-10 |
Chief Executive Officer | 64 | 14-11-22 | |
Maria Freire
BRD | Director/Board Member | 69 | 02-06-21 |
Director/Board Member | 54 | 01/01 | |
Jesus B. Mantas
BRD | Director/Board Member | 55 | 19-06-19 |
Susan Langer
BRD | Director/Board Member | - | 26-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 169 160 798 | 144 356 479 ( 85,34 %) | 23 800 000 ( 14,07 %) | 85,34 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
DENALI THERAPEUTICS INC. 9.23% | 12 751 365 | 9.23% | 252 222 000 $ |
SAGE THERAPEUTICS, INC. 10.38% | 6 241 473 | 10.38% | 134 066 840 $ |
14 652 466 | 8.26% | 16 996 861 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. |
Biotechnology
|
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-16,67% | 31,34 mld. | |
+0,44% | 90,78 mld. | |
+9,61% | 43,96 mld. | |
+44,99% | 23,45 mld. | |
-9,42% | 16,48 mld. | |
-25,92% | 15,03 mld. | |
-9,27% | 12,79 mld. | |
-7,57% | 12,19 mld. | |
+0,07% | 8,5 mld. | |
-11,81% | 7,82 mld. |
- Beurs
- Aandelen
- Aandeel Biogen Inc. - Nasdaq
- Onderneming Biogen Inc.